These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 30319054)

  • 41. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
    Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
    In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
    Zhang Q; Chen WM; Zhang XX; Zhang HX; Wang HC; Zheng FY; Zhu FF
    Oncol Rep; 2017 Mar; 37(3):1826-1832. PubMed ID: 28184918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
    Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
    Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
    Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
    Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer.
    Lee JY; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Ann Surg Oncol; 2014 Aug; 21(8):2762-6. PubMed ID: 24770785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
    Bi SN; Dai SZ; Yao Q; Che YC; Wang N
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):288-91. PubMed ID: 18788634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
    Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
    Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.
    Surówka J; Wertel I; Okła K; Bednarek W; Tarkowski R; Kotarski J
    Clin Transl Oncol; 2017 Dec; 19(12):1489-1497. PubMed ID: 28589429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.
    Yildiz Y; Kabadayi G; Yigit S; Kucukzeybek Y; Alacacioglu A; Varol U; Taskaynatan H; Salman T; Oflazoglu U; Akyol M; Tarhan MO
    J BUON; 2019; 24(4):1549-1554. PubMed ID: 31646807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
    Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
    Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
    Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
    BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
    Wimberger P; Chebouti I; Kasimir-Bauer S; Lachmann R; Kuhlisch E; Kimmig R; Süleyman E; Kuhlmann JD
    Gynecol Oncol; 2014 Jun; 133(3):467-72. PubMed ID: 24713547
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
    Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
    Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?
    Lennox GK; Eiriksson LR; Reade CJ; Leung F; Mojtahedi G; Atenafu EG; Ferguson SE; Murphy J; Diamandis EP; Kulasingam V; Bernardini MQ
    Int J Gynecol Cancer; 2015 Jun; 25(5):809-14. PubMed ID: 25855958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.